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STRAIN DIFFERENCES IN THE
CARCINOGENIC ACTION OF N-
ETHYL-N-NITROSOUREA (ENU) IN
MICE. C. E. SEARLE and E. L. JONES.
Departments of Cancer Studies and Path-
ology, University of Birmingham Medical
School.
Nitrosamide carcinogens induce neural
tumours with great ease in rats but not in
mice. When mice of 4 inbred strains were
treated neonatally with ENU (10-160 mg/kg
body weight) some DBA and IF mice deve-
loped neural tumours (Searle and Jones,
Nature, Lond., 1972, 240, 559) but tumours
induced were predominantly of the liver
(C57BL, DBA), lung (A) and thymus and/or
spleen (A, DBA). Many mice had multiple
primary tumours. The multipotential action
of ENU in mice is relevant to the possibility
that some human tumours might be caused by
substances with a nitrosamide-like action.
Though sensitive to carcinogenic polycyclic
hydrocarbons, IF mice proved relatively
resistant to carcinogenesis by ENU, recalling
earlier findings with 4-nitroquinoline N-oxide
(Searle and Spencer, Br. J. Cancer, 1966, 20,
877).
ZEARALENONE IN THE DIET,
PODOPHYLLOTOXIN IN THE WOOD
SHAVINGS BEDDING, ARE LIKELY
TO AFFECT THE INCIDENCE
OF "SPONTANEOUS" TUMOURS
AMONG LABORATORY ANIMALS.
R. SCHOENTAL. Department of Pathology,
Royal Veterinary College, London.
One- of the factors responsible for the
variations in the incidence of endocrine
tumours among laboratory animals may be
zearalenone, the oestrogenic secondary meta-
bolite of Fusarium graminearum (Gibberella
zeae) and of certain other fungi, which
sometimes contaminate cereals.
Among wood constituents, which may
contribute to the carcinogenic effects of
certain wood shavings bedding (Schoental,
Lab. Animals, 1973, 7, 47) are oc,fl-unsaturated
lignin aldehydes, and possible lignans such as
podophyllotoxin, present in red cedar wood,
Juniperus virginiana L. (Hartwell et al., J.
Am. chem. Soc., 1953, 75, 235).
LYMPHOCYTE DEPENDENT CY-
TOTOXIC ANTIBODY ACTIVITY
AGAINST HUMAN MELANOMA
ANTIGENS. R. VANWIJCK, M.-C. MOOR,
S. MALEK-MANSOUR and P. RUSTIN. Depart-
ments of Plastic Surgery and Dermatology,
University of Liege, Belgium.
A lymphocyte dependent cytotoxic anti-
body activity has been detected in the serum
of 5 out of 38 melanoma patients. Three of
them had been free of disease for at least a
year and a half. The 2 others were patients
submitted to a nonspecific immunotherapy
by 2-4 dinitrochlorobenzene (DNCB). The
cytotoxic mechanism induced by this anti-
body activity was found to be highly effective
in terms ofthe number of melanocytes which
can be killed by a given number of lymphoid
cells and the antibody concentration needed
to induce killing. These antibodies can
increase the killing of allogeneic melanoma
cells not only by sensitized lymphocytes
(potentiation) but also by non-sensitized
lymphocytes (" arming "). Arming and po-
tentiating activities are usually but not
always associated.
The demonstration ofantibody dependent
lymphocyte activity against melanoma cells
may have important implications in manage-
ment and therapy of malignant melanoma.
STUDIES ON A NONSPECIFIC AND
NON-CYTOTOXIC CYTOSTATIC FAC-
TOR PRODUCED BY MACROPHAGES.
F. J. LEJEUNE and R. REGNIER. Departments
of Surgery and Radiotherapy, Institute Jules
Bordet, Brussels.
In vitro studies showed that peritoneal
macrophages (PM) taken from normal un-
sensitized mice, exert a strong nonspecific
cytostatic effect on the Harding-Passey
Melanoma (HPM) and on mouse mammary
tumour (BALB/C syngeneic). This effect
was assessed by cell counts and tritiated
thymidine uptake. Non-adherent cells had
no effect. No cytotoxicity was found according
to the chromium release test.
A two-step cell culture system was used
to assay separately PM lysates and PM
supernatants. PM lysates, in most instances,
exhibited a serum independent cytostatic
effect. However, PMlysatesfrom some young
mice (C57 B1 and BDF1) had no effect when
obtained from serum-free cultures, while
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they inhibited 75% of the thymidine uptake,
when taken from PM cultures with as little as
0.5%0 foetal bovine serum. Further, it was
found that sera from various species could
produce this macrophage activation. The
supernatant of 72 h cultured PM contained
a cytostatic factor (CF) which could inhibit
50-75% of the thymidine incorporation in
equal number of HPM cells. CF was found
to be thermostable and dialysable.
These findings suggest that some normal
serum components could substitute in vitro
for the in vivo activation of PM.
DEMONSTRATION OF THE ANTI-
TUMOUR EFFECT OF IN VIVO
MACROPHAGE ACTIVATION. I. PARR.
Chester Beatty Research Institute, Sutton,
Surrey.
Macrophages from mice sensitized to one
antigen become nonspecifically cytotoxic to
tumour cells after meeting the same antigen
again (Evans and Alexander, Nature, Lond.,
1972, 236, 168). This transformation was
termed macrophage activation. Where a
condition of chronic infection has become
established, persistence of the infecting
antigen can lead to the presence of activated
macrophages (Hibbs, Lambert and Remming-
ton, J. infect. Dis., 1971, 124, 587). No
activated macrophages couldbedemonstrated
in the peritoneal cavities of mice that had
been injected i.p. with B.C.G. 2 weeks
previously. This may be a reflection of the
fact that the strain of B.C.G. (Glaxo) that
was used does not persist in large numbers in
the peritoneal cavities of mice. Reintroduc-
tion of the antigen (as PPD) into the same
site as the tumour cells protected against
syngeneic tumour challenge with either
lymphoma (L5178Y in DBA/2 mice) or
fibrosarcoma (FS6inC57B1 mice). Peritoneal
exudate (PE) cells from B.C.G. sensitized mice
could be made cytotoxic to fibrosarcoma
cells by re-addition of the antigen.
IMMUNOLOGICAL DEPLETION
CONTRIBUTING TO FAMILIAL
HODGKIN'S DISEASE. J. J. FENELLY
and A. McBRIDE. St Vincent's Hospital,
Dublin.
In a family of 5 girls, 3 of whom have
Hodgkin's disease, pathogenetic possibilities
were studied, i.e. HL-A typing, chromosomes,
detailed blood group analysis, humoral anti-
body (immunoglobulins, serum protein
electrophoresis), cell mediated immunity
(PPD, DNCB, LTT and MLC), viral studies
(Epstein-Barr, other herpesviruses, CMV)
Australia antigen.
The major abnormality was a defect of
cell mediated immunity detected in both
parents and the 5 girls as evidenced by
very poor in vitro lymphocyte blastogenesis
with PHA in all 7. The fourth sister (recent
infectious mononucleosis), and the mother,
were anergic to PPD and DNCB while the
father and fifth sister (recurrent herpes
labialis) both had 4+ DNCB, reaction. In
addition, the mother had an M band on serum
protein electrophoresis.
Our findings suggest that a familial cell
mediated immune depletion is providing a
milieu wherein viral infection may manifest
itself as Hodgkin's disease.
SOME ASPECTS OF THE USE OF
B.C.G. IN THE TREATMENT OF
ADVANCED MALIGNANT DISEASE.
R. M. GRANT, R. M. MACKIE, A. J. COCHRAN,
D. HOYLE and C. Ross. Departments of
Pathology and Dermatology, Western Infir-
mary, Glasgow.
We have usedB.C.G. (Glaxopercutaneous)
in the treatment of 7 patients with advanced
malignant disease.
One patient with malignant melanoma
showed regression of more than 70 B.C.G.
injected subcutaneous metastases: the rate
at which new deposits developed declined
and there was only minimal spread to internal
organs. Intra-tumoral B.C.G. was followed
by regression and eventual sloughing of
approximately 90% of an extensive fun-
gating tumour in a patient with local re-
currence of breast cancer in the mastectomy
scar. Local reaction to intratumoral B.C.G.,
without retardation in the progression of the
disease, was observed in a patient with
malignant melanoma while prolongation of
survival was noted in another patient who
had a large solitary lung metastasis. There
was no detectable response to B.C.G. in the
remaining 3 cases.
Pyrexia, lassitude and anorexia occurred
as transient side-effects of B.C.G. therapy in
3 patients. One patient experienced a severe
generalized B.C.G. infection.